Broderick Named UCNI Director
Joseph Broderick, MD, has been named overall director of the University of Cincinnati Neuroscience Institute (UCNI) effective Jan. 1, 2014.
Broderick, who has served as UCNI research director, will assume the new position as John Tew, MD, who has served as clinical director, steps into new roles at the College of Medicine and UC Health following 15 years of leadership.
As part of his new role, Broderick will end his 13-year tenure as Albert Barnes Voorheis Chair of Neurology and Rehabilitation Medicine on Dec. 31. Brett Kissela, MD, will become chair of the department Jan. 1.
Since it began in 1998, UCNI has focused on multi-disciplinary and multi-departmental care of patients with neurologic and psychiatric disorders, research to advance the understanding and treatment of these diseases and educating patients, their families and the medical community.
Aided by community and institutional support, UCNI has substantially increased its faculty and impact with nine disease-specific centers and noted programs, such as neurocritical care, spanning several of the centers.
Tew co-founded UCNI with Robert Lukin, MD, and Fred Samaha, MD. A professor of neurosurgery, radiology and surgeryand for 20 years, chair of the Department of NeurosurgeryDr. Tew pioneered work in the areas of microsurgery, lasers, image-guided surgery, trigeminal neuralgia and brain tumor treatments.
Assisting Broderick in the leadership of UCNI will be Anya Sanchez, MD, who will continue as administrative director, a position she has held for the past four years. Mario Zuccarello, MD, Frank H. Mayfield Endowed Chair for Neurological Surgery and chair of the UC Department of Neurosurgery, will lead the stakeholder's advisory group for UCNI.
The administrative team will continue focusing on innovative patient-centered care of neurologic and psychiatric patients across UC Health, strengthening current centers and growing new centers and programs, and expanding the institutes research and educational missions.
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.